ATE490262T1 - Abschwächung der immunogenizität von fusionsproteinen - Google Patents
Abschwächung der immunogenizität von fusionsproteinenInfo
- Publication number
- ATE490262T1 ATE490262T1 AT02757870T AT02757870T ATE490262T1 AT E490262 T1 ATE490262 T1 AT E490262T1 AT 02757870 T AT02757870 T AT 02757870T AT 02757870 T AT02757870 T AT 02757870T AT E490262 T1 ATE490262 T1 AT E490262T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- immunogenicity
- attenuation
- epitopes
- relates
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28062501P | 2001-03-30 | 2001-03-30 | |
PCT/US2002/009815 WO2002079232A2 (en) | 2001-03-30 | 2002-03-30 | Reducing the immunogenicity of fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE490262T1 true ATE490262T1 (de) | 2010-12-15 |
Family
ID=23073904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02757870T ATE490262T1 (de) | 2001-03-30 | 2002-03-30 | Abschwächung der immunogenizität von fusionsproteinen |
Country Status (19)
Country | Link |
---|---|
US (5) | US6992174B2 (de) |
EP (2) | EP2311882A1 (de) |
JP (2) | JP4638129B2 (de) |
KR (1) | KR20030087040A (de) |
CN (1) | CN100488984C (de) |
AT (1) | ATE490262T1 (de) |
AU (1) | AU2002306976B2 (de) |
BR (1) | BR0208207A (de) |
CA (1) | CA2442363C (de) |
DE (1) | DE60238472D1 (de) |
DK (1) | DK1373301T3 (de) |
ES (1) | ES2356620T3 (de) |
HU (1) | HUP0303753A2 (de) |
MX (1) | MXPA03008715A (de) |
PL (1) | PL209110B1 (de) |
PT (1) | PT1373301E (de) |
RU (1) | RU2333919C2 (de) |
WO (2) | WO2002079415A2 (de) |
ZA (1) | ZA200308430B (de) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE267215T1 (de) * | 1997-12-08 | 2004-06-15 | Lexigen Pharm Corp | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
JP2002511432A (ja) * | 1998-04-15 | 2002-04-16 | レキシジェン ファーマシューティカルズ コーポレイション | 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強 |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
HUP0202442A3 (en) * | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
PT1294401E (pt) * | 2000-06-29 | 2007-11-09 | Merck Patent Gmbh | Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas |
KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20120148585A1 (en) * | 2001-05-01 | 2012-06-14 | Andrew Saxon | Fusion molecules and methods for treatment of immune diseases |
DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
DE10122140A1 (de) * | 2001-05-08 | 2002-11-28 | Apotech Res & Dev Ltd | Rekombinante Fusionsproteine und deren Trimere |
ATE542137T1 (de) * | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7611700B2 (en) * | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
KR101197500B1 (ko) * | 2002-11-15 | 2012-11-09 | 니프로 가부시키가이샤 | 리포솜 |
WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
CA2520254A1 (en) * | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
US20070161087A1 (en) * | 2003-05-29 | 2007-07-12 | Wolfgang Glaesner | Glp-1 fusion proteins |
US7452966B2 (en) * | 2003-06-12 | 2008-11-18 | Eli Lilly And Company | GLP-1 analog fusion proteins |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
CN100453556C (zh) | 2003-10-16 | 2009-01-21 | 麦克罗梅特股份公司 | 多特异性的去免疫化cd3结合物 |
US20050142133A1 (en) * | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
EP2221315A1 (de) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Verfahren zur Erzeugung von Proteinvarianten mit erhöhtem Wirtsstranginhalt und Zusammensetzungen davon |
CN100427599C (zh) * | 2003-12-26 | 2008-10-22 | 吉林大学第一医院 | Albsin/il-18mat杂交细胞因子 |
DE602004013372T2 (de) | 2003-12-30 | 2009-07-02 | Merck Patent Gmbh | Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung |
RU2370276C2 (ru) * | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
AU2005203962C1 (en) * | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
ES2330860T3 (es) | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
PL1737961T3 (pl) | 2004-03-19 | 2013-12-31 | Merck Patent Gmbh | Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005097202A2 (en) * | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP1919950A1 (de) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimierte fc-varianten |
MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
EA014226B1 (ru) | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
CA2581423A1 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
JP4652414B2 (ja) | 2004-11-12 | 2011-03-16 | ゼンコー・インコーポレイテッド | FcRnとの変化した結合を有するFc変異体 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
WO2006068910A1 (en) | 2004-12-22 | 2006-06-29 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
CA2595169A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
WO2007012188A1 (en) * | 2005-07-27 | 2007-02-01 | Qinghua Wang | GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
EP1931709B1 (de) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc-varianten mit optimierten rezeptorbindungseigenschaften |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
RU2426743C2 (ru) | 2005-12-21 | 2011-08-20 | Микромет Аг | Фармацевтические композиции с устойчивостью к растворимому сеа |
KR101397290B1 (ko) * | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-cd19 항체 |
PT1966238E (pt) | 2005-12-30 | 2012-07-31 | Merck Patent Gmbh | Uso de hsp70 como um regulador de atividade enzimática |
WO2007085814A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
EP2038417A2 (de) * | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen |
WO2008045380A2 (en) * | 2006-10-04 | 2008-04-17 | Codon Devices, Inc. | Nucleic acid libraries and their design and assembly |
WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
CN103755789B (zh) | 2007-01-30 | 2016-12-07 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
MX2009011870A (es) | 2007-05-02 | 2009-11-12 | Ambrx Inc | Polipeptidos de interferon beta modificados y usos de los mismos. |
GB2451928B (en) * | 2007-06-21 | 2011-03-16 | Angelica Therapeutics Inc | Modified Toxins |
US8137979B2 (en) * | 2007-06-25 | 2012-03-20 | Qinetiq Limited | Preconcentrator device |
WO2009012600A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
PL2808343T3 (pl) | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
EP2376105B1 (de) | 2008-12-18 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc für immuntherapie |
RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
EP2398494A4 (de) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteine und anwendungsverfahren dafür |
EA201171259A1 (ru) * | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
MX354555B (es) | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. |
PT2440228T (pt) | 2009-06-08 | 2018-12-24 | Amunix Operating Inc | Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos |
JP6166041B2 (ja) | 2009-06-15 | 2017-07-19 | バレリオン セラピューティクス, エルエルシー | ミオチューブラリン1(mtm1)ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物 |
WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8932588B2 (en) | 2009-11-05 | 2015-01-13 | Teva Pharmaceuticals Australia Pty. Ltd. | Treatment of cancer involving mutated KRAS or BRAF genes |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
EP2536756B1 (de) | 2010-02-16 | 2018-04-25 | MedImmune, LLC | Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
ES2876421T3 (es) * | 2011-04-13 | 2021-11-12 | Bristol Myers Squibb Co | Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos |
JP6430828B2 (ja) * | 2011-05-05 | 2018-11-28 | アルブミディクス リミティド | アルブミン変異体 |
CN102222177A (zh) * | 2011-07-08 | 2011-10-19 | 上海生物信息技术研究中心 | 抗体蛋白的分子改造辅助预测方法 |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
CA2864904C (en) | 2012-02-15 | 2023-04-25 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
EP3549953A1 (de) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Rekombinante faktor-viii-proteine |
CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
WO2013184216A1 (en) | 2012-06-05 | 2013-12-12 | Amunix Operating Inc. | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency |
US9714291B2 (en) * | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
US10017581B2 (en) | 2013-02-20 | 2018-07-10 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
JP2016519651A (ja) | 2013-03-15 | 2016-07-07 | アンジェリカ セラピューティックス,インク. | 改質された毒素 |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
WO2015085311A1 (en) | 2013-12-07 | 2015-06-11 | Case Western Reserve University | Compositions and methods of treating thrombosis |
JP6730926B2 (ja) | 2014-01-08 | 2020-07-29 | プロージット ソウル バイオテクノロジー (ベイジン) カンパニー リミテッド | 融合ポリペプチドおよび使用方法 |
US10221250B2 (en) | 2014-01-13 | 2019-03-05 | Valerion Therapeutics, Llc | Internalizing moieties |
JP6731346B2 (ja) | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2950178A1 (en) * | 2014-06-06 | 2015-12-10 | The California Institute For Biomedical Research | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof |
US10124073B2 (en) | 2014-08-04 | 2018-11-13 | Case Western Reserve University | Targeting peptides and methods of use |
JP2017536091A (ja) | 2014-10-02 | 2017-12-07 | シティ・オブ・ホープCity of Hope | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 |
WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
WO2016149643A2 (en) * | 2015-03-18 | 2016-09-22 | Omnicyte | Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof |
US11020454B2 (en) | 2015-07-15 | 2021-06-01 | Prosit Sole Biotechnology (Beijing) Co. Ltd | Fusion polypeptides and methods of use |
WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
CN114853907A (zh) | 2015-11-13 | 2022-08-05 | 达纳-法伯癌症研究所有限公司 | 用于癌症免疫疗法的nkg2d-ig融合蛋白 |
EP4011919A3 (de) | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Relaxin-immunglobulin-fusionsproteine und verfahren zur verwendung |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CA3031168A1 (en) | 2016-08-12 | 2018-02-15 | Merck Patent Gmbh | Combination therapy for cancer |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3496742A4 (de) | 2016-12-01 | 2020-04-08 | University Of South Florida | Peptidkörper, zusammensetzungen daraus und verfahren zur behandlung von vorhofflimmern |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3873611A1 (de) | 2018-11-01 | 2021-09-08 | Merck Patent GmbH | Anti-tim-3-antikörper |
EP3873612A2 (de) | 2018-11-01 | 2021-09-08 | Merck Patent GmbH | Verfahren zur verabreichung von anti-tim-3-antikörpern |
JP2022530216A (ja) * | 2019-04-23 | 2022-06-28 | エルジー・ケム・リミテッド | 免疫グロブリンのFc領域およびGDF15を含む融合ポリペプチド |
JP2022543669A (ja) * | 2019-08-08 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規抗原結合分子フォーマット |
US20230287040A1 (en) | 2019-11-13 | 2023-09-14 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
Family Cites Families (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US166877A (en) * | 1875-08-17 | Improvement in electric lights | ||
US193570A (en) * | 1877-07-24 | Improvement in washing-boards | ||
US147311A (en) * | 1874-02-10 | Improvement in electric telegraphs | ||
US44423A (en) * | 1864-09-27 | Improved screw for music-stools | ||
US142374A (en) * | 1873-09-02 | Improvement in stopping mechanisms for doubling and twisting machines | ||
US49227A (en) * | 1865-08-08 | Improvement in construction of railway trains and cars | ||
US12789A (en) * | 1855-05-01 | Office | ||
US166163A (en) * | 1875-07-27 | Improvement in bee-hives | ||
US192222A (en) * | 1877-06-19 | Improvement in watches | ||
US53539A (en) * | 1866-03-27 | Improvement in revolving fire-arms | ||
US105294A (en) * | 1870-07-12 | Erasmus w | ||
US3529A (en) * | 1844-04-10 | yvolfe | ||
US81664A (en) * | 1868-09-01 | Island | ||
US348237A (en) * | 1886-08-31 | richards | ||
US1803686A (en) * | 1923-11-23 | 1931-05-05 | Herman A Brassert | Gas production |
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4469797A (en) * | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
EP0158198A1 (de) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA und ihre Verwendung |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4667016A (en) * | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
EP0237019A3 (de) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
JPS63267278A (ja) | 1986-03-14 | 1988-11-04 | Toray Ind Inc | インタ−フエロン結合体を暗号化する塩基配列 |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
EP0318554B2 (de) | 1987-05-21 | 2005-01-12 | Micromet AG | Multifunktionelle proteine mit vorbestimmter zielsetzung |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
PT89121A (pt) | 1987-12-04 | 1989-12-29 | Du Pont | Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
ATE123065T1 (de) * | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | Proteine und deren herstellung. |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
EP0765937B1 (de) | 1989-09-20 | 2002-11-27 | Abbott Laboratories | Verfahren zur Herstellung von Fusionsproteinen |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
KR100221066B1 (ko) | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
DK0433827T3 (da) | 1989-12-22 | 1998-09-28 | Hoffmann La Roche | Cytotoksisk lumfocytmodningsfaktor |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991013166A1 (en) | 1990-03-02 | 1991-09-05 | Abbott Biotech, Inc. | Antibody constructs with enhanced binding affinity |
ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
JPH06504262A (ja) | 1990-07-27 | 1994-05-19 | レブリゲン コーポレーション | 脈管形成性の病気の処置用の新規な方法と組成物 |
EP0556328A4 (en) | 1990-11-09 | 1994-06-08 | Abbott Lab | Bridging antibody fusion constructs |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
KR100237968B1 (ko) | 1990-12-05 | 2000-01-15 | 한센 핀 베네드 | 변화된 에피토프를 지닌 단백질 및 그 제조방법 |
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US5376367A (en) | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
ATE260971T1 (de) | 1992-04-01 | 2004-03-15 | Univ Rockefeller | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
WO1993020185A1 (en) | 1992-04-01 | 1993-10-14 | Steinman Ralph M | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
EP0615451B1 (de) * | 1992-05-26 | 2005-12-07 | Immunex Corporation | Neue zytokine die cd30 binden |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
US5429199A (en) * | 1992-08-26 | 1995-07-04 | Kennametal Inc. | Cutting bit and cutting insert |
DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
EP0627932B1 (de) | 1992-11-04 | 2002-05-08 | City Of Hope | Antikörperkonstrukte |
CA2147499C (en) * | 1992-11-05 | 2010-10-19 | Ron S. Israeli | Prostate-specific membrane antigen |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
AU6816194A (en) * | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
WO1994024160A2 (en) | 1993-04-21 | 1994-10-27 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
AU6776194A (en) | 1993-04-28 | 1994-11-21 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
WO1994025055A1 (en) * | 1993-04-29 | 1994-11-10 | Abbott Laboratories | Erythropoietin analog compositions and methods |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
AU689214B2 (en) | 1994-02-01 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fusion proteins that include antibody and nonantibody portions |
WO1995028427A1 (en) | 1994-04-15 | 1995-10-26 | Imclone Systems Incorporated | Chimeric interleukin-3/mutein interleukin-6 lymphokine |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
IL113509A (en) * | 1994-04-26 | 2005-12-18 | Childrens Medical Center | Angiostatin protein preparations and methods of use |
DE69522216T2 (de) | 1994-05-13 | 2002-05-02 | Biovation Ltd | Zielzellen-bindende chimäre Peptide |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1996004388A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Novel compounds |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
EP0706799B1 (de) | 1994-09-16 | 2001-11-14 | MERCK PATENT GmbH | Immunokonjugate |
WO1996018412A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
AU712585B2 (en) * | 1995-03-10 | 1999-11-11 | Genentech Inc. | Receptor activation by gas6 |
US5719266A (en) * | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
AU5893796A (en) | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
GB9511935D0 (en) | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
NL1000614C2 (nl) * | 1995-06-20 | 1996-12-23 | Leer Koninklijke Emballage | Werkwijze voor het vervaardigen van een gelamineerd produkt. |
US5736852A (en) * | 1995-06-21 | 1998-04-07 | Alliedsignal Truck Brake Systems Co. | Circuit and method for conditioning a wheel speed sensor signal |
CN1195293A (zh) * | 1995-06-30 | 1998-10-07 | 伊莱利利公司 | 治疗糖尿病的方法 |
US6406689B1 (en) * | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
KR19990066981A (ko) | 1995-10-23 | 1999-08-16 | 윌리엄 뉴우 | 치료용 맥관형성억제 조성물 및 방법 |
AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
CZ9802013A3 (cs) | 1995-12-27 | 1998-09-16 | Genentech, Inc. | Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US6046310A (en) | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
JP2002514161A (ja) | 1996-07-02 | 2002-05-14 | バー イラン ユニバーシティー | ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ(置換)アルキレンブチレート |
AU4075897A (en) | 1996-08-16 | 1998-03-06 | Roger Lallone | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0973550B1 (de) * | 1997-04-11 | 2002-10-09 | G.D. SEARLE & CO. | Antagonistische anti-avb3 integrin antikörper |
JP4086908B2 (ja) | 1997-04-17 | 2008-05-14 | アムジエン・インコーポレーテツド | 安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法 |
GB2339430A (en) * | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
GB9712892D0 (en) * | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
WO1999002709A1 (en) * | 1997-07-10 | 1999-01-21 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
CA2296770A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
ATE267215T1 (de) * | 1997-12-08 | 2004-06-15 | Lexigen Pharm Corp | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
WO1999043713A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
JP2002511432A (ja) | 1998-04-15 | 2002-04-16 | レキシジェン ファーマシューティカルズ コーポレイション | 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強 |
RU2217168C2 (ru) * | 1998-04-17 | 2003-11-27 | Лексиген Фармасьютикэлс Корпорейшн | Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина |
AU3655899A (en) | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
CA2328490A1 (en) | 1998-05-14 | 1999-11-18 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fused protein |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
WO1999062944A2 (en) | 1998-06-03 | 1999-12-09 | The Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of using the same |
DE69933216T2 (de) | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
EP1105427A2 (de) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Herstellung von modifizierten molekülen mit mit erhöhten halbwertszeiten |
ATE462725T1 (de) | 1998-08-25 | 2010-04-15 | Merck Patent Gmbh | Expression und export von angiostatin und endostatin als immunofusins |
US6646113B1 (en) | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
EP1813624B1 (de) | 1998-10-23 | 2010-08-11 | Amgen Inc. | Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie |
CN1202128C (zh) * | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
HUP0105090A2 (hu) * | 1999-01-07 | 2002-04-29 | Lexigen Pharmaceuticals Corporation | Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában |
DE60027409T2 (de) * | 1999-02-12 | 2007-04-12 | Amgen Inc., Thousand Oaks | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
DE60041183D1 (de) | 1999-05-06 | 2009-02-05 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
JP3660880B2 (ja) | 1999-05-07 | 2005-06-15 | ジェネンテック・インコーポレーテッド | 新規なチンパンジーエリスロポエチン(chepo)ポリペプチドおよびこれをコードする核酸 |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
BR0010725A (pt) * | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
WO2000078334A1 (en) | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
HUP0202442A3 (en) * | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
EP1228214A2 (de) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietinformen mit verbesserten eigenschaften |
ATE336514T1 (de) * | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
WO2001062298A2 (en) * | 2000-02-24 | 2001-08-30 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
US6946134B1 (en) * | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001088117A2 (en) * | 2000-05-12 | 2001-11-22 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
PT1294401E (pt) * | 2000-06-29 | 2007-11-09 | Merck Patent Gmbh | Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas |
HUP0401300A3 (en) * | 2001-01-18 | 2005-06-28 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
CA2438652A1 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
EP1361891A2 (de) * | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Künstliche fusionsproteine mit verminderter immunogenität |
KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
ATE542137T1 (de) * | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
AU2002316574B2 (en) | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
US6996009B2 (en) * | 2002-06-21 | 2006-02-07 | Micron Technology, Inc. | NOR flash memory cell with high storage density |
WO2004055056A1 (en) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
DE602004013372T2 (de) * | 2003-12-30 | 2009-07-02 | Merck Patent Gmbh | Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung |
RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
ES2330860T3 (es) | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
PT1966238E (pt) * | 2005-12-30 | 2012-07-31 | Merck Patent Gmbh | Uso de hsp70 como um regulador de atividade enzimática |
DK1966244T3 (da) | 2005-12-30 | 2012-04-23 | Merck Patent Gmbh | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 |
KR101397290B1 (ko) | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-cd19 항체 |
EP1999154B1 (de) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Gentechnisch hergestellte heterodimere proteindomänen |
EP2038417A2 (de) * | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen |
-
2002
- 2002-03-29 WO PCT/US2002/009650 patent/WO2002079415A2/en not_active Application Discontinuation
- 2002-03-29 US US10/112,582 patent/US6992174B2/en not_active Expired - Lifetime
- 2002-03-30 DK DK02757870.7T patent/DK1373301T3/da active
- 2002-03-30 HU HU0303753A patent/HUP0303753A2/hu unknown
- 2002-03-30 PT PT02757870T patent/PT1373301E/pt unknown
- 2002-03-30 AU AU2002306976A patent/AU2002306976B2/en not_active Expired
- 2002-03-30 CA CA2442363A patent/CA2442363C/en not_active Expired - Lifetime
- 2002-03-30 EP EP10010015A patent/EP2311882A1/de not_active Withdrawn
- 2002-03-30 ES ES02757870T patent/ES2356620T3/es not_active Expired - Lifetime
- 2002-03-30 RU RU2003129523/13A patent/RU2333919C2/ru not_active IP Right Cessation
- 2002-03-30 WO PCT/US2002/009815 patent/WO2002079232A2/en active Application Filing
- 2002-03-30 DE DE60238472T patent/DE60238472D1/de not_active Expired - Lifetime
- 2002-03-30 EP EP02757870A patent/EP1373301B1/de not_active Expired - Lifetime
- 2002-03-30 KR KR10-2003-7012819A patent/KR20030087040A/ko not_active Application Discontinuation
- 2002-03-30 MX MXPA03008715A patent/MXPA03008715A/es active IP Right Grant
- 2002-03-30 AT AT02757870T patent/ATE490262T1/de active
- 2002-03-30 PL PL366826A patent/PL209110B1/pl unknown
- 2002-03-30 BR BR0208207-1A patent/BR0208207A/pt not_active IP Right Cessation
- 2002-03-30 CN CNB028075056A patent/CN100488984C/zh not_active Expired - Lifetime
- 2002-03-30 JP JP2002577856A patent/JP4638129B2/ja not_active Expired - Fee Related
-
2003
- 2003-10-29 ZA ZA200308430A patent/ZA200308430B/en unknown
-
2005
- 2005-09-23 US US11/233,683 patent/US7601814B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/552,076 patent/US7973150B2/en not_active Expired - Fee Related
-
2010
- 2010-07-02 JP JP2010151743A patent/JP5291671B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-26 US US13/116,830 patent/US8926973B2/en not_active Expired - Fee Related
-
2015
- 2015-01-02 US US14/588,702 patent/US20150141626A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE490262T1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
ATE542137T1 (de) | Immunocytokine mit modulierter selektivität | |
NO20041917D0 (no) | Spesifikke midler som binder humant angiopoietin-2 | |
ATE405647T1 (de) | Rekombinantes gelatin in impstoffen | |
NO20071432L (no) | Fremgangsmate for konsentrasjon av antistoffer of terapeutiske produkter derav. | |
BR9906927A (pt) | Proteìnas de neisseria meningitidis | |
ATE441663T1 (de) | Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten | |
BR9814276A (pt) | Antìgenos de superfìcie | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
DK1185691T3 (da) | Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf | |
DK2327719T3 (da) | Hybrid- og tandemekspression af neisseria-proteiner | |
DE69938302D1 (de) | Neisseria meningitidis antigene und zusammenstellungen | |
CY1111831T1 (el) | Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
EA201100071A1 (ru) | Новые композиции и способы | |
EA200100012A1 (ru) | Мостиковые инденопирролокарбазолы | |
DK1089968T3 (da) | Thyroideahormonanaloger og fremgangsmåder til deres fremstilling | |
EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks | |
DK1845164T3 (da) | Promoterer til ekspression i modificeret vacciniavirus ankara | |
EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
DK1279677T3 (da) | GD3-mimetiske peptider | |
EA200400392A1 (ru) | Связывающий каспазу-8 белок, его получение и применение | |
ATE557034T1 (de) | Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen | |
WO2002062964A3 (en) | Ap1 amine oxidase variants | |
ATE397753T1 (de) | Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung | |
EA200400534A1 (ru) | Стимуляция тимозином генетической иммунизации |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1373301 Country of ref document: EP |